e-learning
resources
European Respiratory Review
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients
Kamel Amraoui, Karim Belhadj, Bernard Maître, Caroline Jannière-Nartey, Jehan Dupuis
Source:
Eur Respir Rev 2013; 22: 93-95
Journal Issue:
March 2013 - 22 (127)
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kamel Amraoui, Karim Belhadj, Bernard Maître, Caroline Jannière-Nartey, Jehan Dupuis. Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients. Eur Respir Rev 2013; 22: 93-95
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021
Long-term treatment with infliximab in patients with sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Year: 2019
Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019
Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
A rare pulmonary complication of myeloma therapy
Source: Breathe 2014; 10: 243-248
Year: 2014
A rare pulmonary complication of myeloma therapy
Source: Case Report 2014
Year: 2014
Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Long-term sirolimus treatment in lymphangioleiomyomatosis
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension.
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Lung toxicity in a patient treated with sunitinib
Source: Eur Respir J 2012; 40: 1300-1303
Year: 2012
Predictive role of
MMP-2
genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy
Source: Annual Congress 2011 - Genetics of airway diseases and treatment
Year: 2011
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept